Infanrix Hexa + Bexsero

Infanrix Hexa + Bexsero refers to the co-administration of two distinct pediatric vaccines: Infanrix Hexa, a hexavalent vaccine, and Bexsero, a multicomponent serogroup B meningococcal vaccine. Infanrix Hexa provides active immunization against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b (Hib). It contains toxoids, inactivated polioviruses, recombinant hepatitis B surface antigen, and purified pertussis antigens. Bexsero (4CMenB) is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B and consists of four main components: factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA), and outer membrane vesicles (OMV) containing PorA P1.4. This combination is commonly used in routine infant immunization schedules. Clinical research, including studies sponsored by CHU de Quebec-Universite Laval, has focused on evaluating the safety, reactogenicity, and potential immunological interactions when these vaccines are administered concurrently at the same visit versus separate visits.

Brand names

Bexsero

Other names

diphtheria + tetanus + pertussis + polio + hepatitis B + HiB-CHU de Quebec-Universite Laval-meningococcal infectionDTaP-IPV-HepB-Hib + Meningococcal group B vaccine4CMenB + Infanrix Hexa